CBD Archives - Green Market Report

Debra BorchardtJune 17, 2022


Big Bang Theory star Dr. Mayim Bialik is suing dozens of websites and online markets that are attaching her name to CBD products without her permission. According to Law360, the star filed a lawsuit in Florida federal court on Thursday. In addition to her extensive career in the entertainment industry, Bialik earned her doctorate in neuroscience. Bialik is also an accomplished author with published works in the genres of young adult and cookbooks.

The court complaint stresses that Bialik “engages in deliberate consideration prior to permitting the commercial use of her name, image, likeness or persona, to ensure that she is associated only with reputable products, entertainment, services and/or companies, and to ensure that the value of her name, image, likeness and persona is not diminished either by association with products, entertainment, services and/or companies which she does not personally support and/or by over-saturation of her name and image.” Her complaint also states that Bialik has never endorsed any cannabidiol products.

(Photo by Jeff Vespa/WireImage)

The complaint suggests that the people behind the websites advertising Mayim Bialik CBD products are based in the Dominican Republic. They attach Bialik’s name to the CBD product and when the consumer clicks to buy, they get redirected to another e-commerce page where the name is dropped.

The complaint even uses an example of sponsored content in SF Weekly stating, “The headline of the article proclaims in large, bolded font: “Mayim Bialik CBD Gummies –
Shocking Scam Report Reveals Must Read Before Buying.” The small script in the byline reflects the anonymous nature of the author who is identified only as “Sponsor.” The photograph of the goods identify the featured Unauthorized CBD Gummies as branded by “Cannaleafz.” The article includes promotional language such as: “With the growing age, your happiness is going to remain with you with the remarkable Mayim Bialik CBD Gummies.” (emphasis in the original). The purchase link prompts consumers to “Order Mayim Bialik CBD Gummies Only Visiting Official Website Today.” When a consumer clicks the purchase link, they are redirected to a Product Sales Page.”

Sasha Cohen Said No Too

Bialik isn’t the only celebrity to get angry about the unauthorized use of their image for cannabis promotions. Comedian Sasha Baron Cohen  the creator of the character “Borat” sued privately-owned Massachusetts cannabis company Solar Therapeutics Inc. and the company’s President Edward Dow III for $9 million. Cohen was angry that his likeness as the character Borat was used without his permission on a billboard that was placed on a busy highway. The lawsuit claims that by using Cohen’s image it looks as if he is endorsing cannabis products. Even though the company removed the billboard, Cohen continued with his lawsuit until recently dropping it this past May.


Debra BorchardtMay 9, 2022


Last week, the Food & Drug Administration (FDA) sent out warning letters to five cannabidiol (CBD) companies for Unapproved New Drugs/Misbranded/Cannabidiol (CBD) Products.

“The FDA is very concerned about the growing popularity of delta-8 THC products being sold online and in stores nationwide. These products often include claims that they treat or alleviate the side effects related to a wide variety of diseases or medical disorders, such as cancer, multiple sclerosis, chronic pain, nausea and anxiety,” said FDA Principal Deputy Commissioner Janet Woodcock, M.D. “It is extremely troubling that some of the food products are packaged and labeled in ways that may appeal to children. We will continue to safeguard Americans’ health and safety by monitoring the marketplace and taking action when companies illegally sell products that pose a risk to public health.”

The companies receiving the letters were  Kingdom Harvest, Delta 8 Hemp, ATLRx Inc., BioMD Plus and M Six Labs Inc. The FDA reviewed all of the company’s websites and said the following:

The claims on your website and social media accounts establish that your products, some of which are available in multiple varieties are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d).

The FDA also zeroed in on the Delta-8 aspects saying:

FDA has also observed a proliferation of products containing another cannabinoid, Delta-8 THC, and has recently expressed serious concerns about products containing Delta-8 THC that include: 1) Delta-8 THC products have not been evaluated or approved by FDA for safe use and may be marketed in ways that put the public health at risk; 2) FDA has received adverse event reports involving Delta-8 THC containing products; 3) Delta-8 THC has psychoactive and intoxicating effects; 4) FDA is concerned about the processes used to create the concentrations of Delta-8 THC claimed in the marketplace; and 5) FDA is concerned about Delta-8 THC products that may be consumed by children, as some packaging and labeling may appeal to children. See https://www.fda.gov/consumers/consumer-updates/5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc. This letter is to inform you that your firm markets Delta-8 THC-containing products, and Delta-8 THC may pose a serious health risk to consumers.

The FDA also took issue with bringing “products into interstate commerce under section 301(ll) of the FD&C Act, 21 U.S.C. 331(ll).”

Mostly the FDA was concerned with companies making unsubstantiated claims about the products.

COVID Claims

The FDA noted that the Kingdom Harvest website said, “Studies Show Our Whole-Spectrum Extract Utilizing CBDa Can Prevent Infection From COVID-19.” The FDA says if a company makes a claim like this then the product is a drug and has to have the appropriate testing in order to make that claim. The FDA wrote, “These products are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners. Therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes.”

Farm Animals

The FDA was also concerned in its warning letters that CBD products were being offered to farm animals that could produce a food products for humans. The FDA wrote,

To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act, 21 U.S.C. §§ 360b, 360ccc, and 360ccc-1. These products are not approved or index listed by the FDA, and therefore these products are unsafe under section 512(a) of the FD&C Act, 21 U.S.C. § 360b(a), and adulterated under section 501(a)(5) of the FD&C Act 21 U.S.C. § 351(a)(5).

Cancer Claims

In addition to Covid claims, the FDA noted in its letter to Delta-8 Hemp that the company was making cancer claims. That letter highlighted a comment from the company’s website that said, “Delta-8 is known to be successful in many cancer treatments.” The FDA told the company, “Your Delta-8 THC products for humans are not generally recognized as safe and effective (GRASE) for their above-referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). ”

Mental Health

While many CBD companies suggest that the product helps anxiety, some of the companies in the latest batch of warning letters went even further. There were suggestions that it could help people suffering from schizophrenia and Alzheimer’s based on very small studies. The FDA is concerned that some patients would stop other medications and use these instead.

No Information

Of course, since the FDA hasn’t set any guidelines for CBD products, the companies aren’t able to introduce any information regarding dosage. The FDA complains the companies aren’t labeling the products correctly, but also won’t allow the companies to express these descriptions.

The FDA has requested written responses from the companies within 15 working days stating how they will address these violations and prevent their recurrence. Failure to promptly address the violations may result in legal action, including product seizure and/or injunction.

Julie AitchesonApril 18, 2022


Legal cannabis loopholes are sparking both innovation and creative evasion in today’s cannabis industry, and a host of law professionals are taking pains to elucidate them for clients in cannabis who risk both profit and loss by operating within them. After doing our due diligence with some of the cannabis industry’s top law professionals, Green Market Report has composed a list of the top five legal loopholes keeping things interesting in cannabis right now.


According to Morgan Davis, founder and CEO of Davis Legal, CBD products for food and beverage consumption present one of the most commonly exploited legal loopholes. CBD is still not FDA-approved, but consumables are commonly available everywhere from gas stations to Whole Foods and online retailers. “There are some states that have enacted regulations allowing for hemp and CBD products for human consumption,” Davis says, “but a majority have not. Nevertheless, a consumer can buy hemp and CBD food and beverage products for consumption in almost every state in the U.S.”

David Feldman, CEO of cannabis strategic advisory firm Skip Intro Advisors, puts Delta-8 at the top of his loophole list, and he’s not alone. Legal Associate Demetria Hamilton, in a blog post for law firm Bryan Cave Leighton Paisner (BCLPDigest.com) states that while Delta-8 THC is derived from CBD extracted from hemp plants and has been found to provide a “high” distinct from Delta-9, it still falls under the Farm Bill’s definition of “hemp”. “In other words,” she writes, “while Delta-8 is another name for Tetrahydrocannabinols, its presence in any quantity provides a risky grey area for brave cannabis producers to work-and profit- within.”

Sex & Wellness

Both Feldman and Davis are of the opinion that the medical marijuana market is another realm where cannabis businesses find workarounds to get their products into consumers’ hands. Davis cites “period care”, such as CBD or THC tampons, which are not FDA-approved and, as “medical devices”, are prohibited from including THC or CBD yet are still available online and throughout the country. Sex and wellness is another avenue for loopholes.  As “medical devices”, sex toys are regulated by the FDA, thereby prohibiting cannabis as an additive. Cannabis is also not approved by the FDA to enhance the sexual experience or treat sexual dysfunction, yet products (e.g. THC strains specifically targeted to enhance sexual experience, infused lubes, cannabis condoms, etc.) that address exactly those needs are gaining in popularity. “The loophole,” says Davis, “is that most of the companies either sell their product as a topical or “novelty item” to avoid the medical device issue. Add in some creative marketing to avoid being prescriptive and, so far, these products have avoided much scrutiny or enforcement.”

Both Davis and Feldman agree that “gift culture” has long been used as a means of circumventing legal restrictions by including cannabis gifts with a different purchase, such as a sticker, patch or poster advertising the company. A “donation economy” offers a similar workaround, and one that has been utilized in California’s medical market for twenty years. Customers make a donation in an amount equivalent to the cost of a cannabis product, then receive the product as a “free gift” as a token of appreciation for the donation.


“Cannabis hospitality” is a sector of the market where legal loopholes are helping cannabis consumers enjoy products outside of their homes. Restaurants or lounges may offer consumption options like joints or edibles without possessing the requisite retail license, while hotels, event spaces and even campgrounds can take advantage of private property laws to allow them to host cannabis consumption on their property. This does not extend to national parks and property owned by the Bureau of Land Management, which adhere to federal regulations and where cannabis and certain CBD products are illegal at all times. State parks may be more flexible depending on the state’s marijuana regulations. For example, information officer for California State Parks Adeline Yee confirms that “persons 21 and older may possess up to 28.5 grams of marijuana” at California state parks. Smoking or ingesting cannabis in California state parks is still illegal, however, and may only occur on private property.

Morgan Davis observes that some of today’s hottest trends in cannabis are operating in many of these legal grey areas, driven by those who choose to believe that if something is not very specifically prohibited by law, it is legal. “It’s still an exciting interval to watch,” Davis says. “The first one through the wall might get the bloodiest, but they’ll clear the path for all of the monumental ways this plant can transform lives.”


Julie AitchesonFebruary 2, 2022


Pricing schemes for CBD products are as variable as the products themselves and impacted by such factors as quality of ingredients, potency, and production. In a pricing analysis that compared over 3000 CBD products across 100 brands, a recent analysis conducted by Leafreport found that the price difference between the cheapest and most expensive topicals increased to 11142% as of the end of November 2021. In April of 2021, that difference was 4718%. Leafreport created a price index to compare brands:  “Bargain grade” brands (priced ranging from $.01-$.076/mg CBD), “Market grade” brands (priced ranging from $.077-$$.167/mg CBD), and “Pricey grade” brands (priced above $.168/mg CBD). 

“Bargain grade” CBD brands analyzed in the report included Extract Labs, Vida Optima and Erth Hemp among others while “Market brands” featured names like Receptra Naturals, cbdmd (OTC: YCBD) and Elixinol (OTC: ELLXF). Upmarket labels like Foria, PureKana and Kushly made the list of “Pricey brands” by Leafreport’s metrics. The vast pricing spread between “bargain” and “pricey” CBD products is not new to the market. Still, the ever-widening gap is noteworthy, as are a number of Leafreport’s other findings related to the discrepancy.  

While CBD topicals and creams showed themselves to range most widely in pricing among product categories, there was also a significant 3561% gap between the most least expensive products across all products. The difference between the cheapest and most expensive products in the edibles category was also noteworthy at 5100%. Gummies and pet tinctures posted the least difference in pricing between “bargain” and “pricey” brands at 833% and 858% respectively.

Leafreport spoke to a variety of CBD industry experts in order to gain a greater perspective on the factors that influence pricing. Responses from Laura Fuentes of Green Roads CBD and Winston Peki of Herbonaut highlight the current lack of regulation in the CBD industry, which allows some companies to skimp on materials and the production process without penalty. This can seriously affect a product’s purity and potency, but due to ongoing issues of inaccurate labeling and false product claims, cost-conscious customers often don’t realize that they’ve purchased an inferior product until it’s too late. 

Peki specifies that there are three production factors that influence price: hemp cultivation processes and the hemp plant parts used; extraction type, and vertical integration of the brand, which enables manufacturers to optimize costs by having more control over each step of the process. He takes issue with comparing CBD product prices based on how much CBD you get for a certain price, citing the value of other hemp compounds that can enhance and individualize a product’s effects. When it comes to topicals and edibles, the difference between an isolate and full-spectrum hemp makes a big difference in cost, as does the use of “boilerplate” formulations that are cheaper because production is standardized rather than curated. Jim Higdon of Cornbread Hemp affirms that the diversity and quality of ingredients are a major factor in pricing such as when the product has a certified organic designation.

So what does Leafreport’s brand data reveal that might be of use to CBD consumers ranging from the budgetista to the aficionado with ample discretionary funds? Leafreport breaks this down by product category. For example, Industrial Hemp Farms showed up as the least expensive brand on the market across all CBD products (unchanged from the prior year’s report). The brand offers the cheapest full and broad spectrum tinctures, though, in a previous review of their products, Leafreport found that several products showed higher than the acceptable variance for potency levels. Her Highness came in as the most expensive brand of full and broad spectrum tinctures, but Leafreport notes a dearth of information available from the company about ingredient sourcing and production. Industrial Hemp Farms sells the least expensive topicals and creams as well, with Kushly ranking as the priciest brand in this category and overall. 

The discrepancy in price between high and low-end brands was found to have increased within seven out of ten product categories since 2020 according to Leafreport’s data. This indelibly points to the ongoing reality of an unregulated market—a pressing issue with a resolution that is far from imminent.

Video StaffDecember 27, 2021


Rachel Rapinoe is best known for her days as a former professional soccer player, but she also co-founded and is the CEO of CBD company Mendi. Rapinoe created the products for athletes as a recovery tool. She uses CBD every day as well. Rapinoe says starting the company was the easy part, but staying with it is the hard part. She has no plans on quitting now and keeps working to spread the word of The Mendi Co.

Julie AitchesonDecember 7, 2021


With December upon us and hemp harvest season coming to a close, the cannabis industry is facing a sobering bust following the great CBD boom. The November 2021 Hemp Benchmarks Report contains results from an analysis of financial findings from publicly traded CBD companies, which reflect a stagnant 2021 market. However, hemp-derived THC (Delta-8) companies are seeing solid revenues despite some decline in wholesale prices. This was the case for LFTD, which saw $29 million in combined sales in the third quarter, while longstanding hemp CBD company Charlotte’s Web (OTC: CWBHF), which has the largest U.S. market share, reported a revenue decline of 6% year-over-year. Other publicly traded CBD companies such as cbdmd and CV Sciences reported similar trends.

Wholesale prices for various types of extracted CBD continue in a downward trend and, according to Hemp Benchmarks, the amount of hemp acreage planted and harvested successfully this year declined by roughly half compared to 2020.  The glut of hemp biomass and hemp-derived CBD products in the market, lack of growth in demand for non-intoxicating cannabinoids and the rise in popularity of synthetics manufactured from hemp-derived CBD point to more trouble ahead for CBD product sales. Other impacts include regulatory uncertainty and a drop in consumer spending due to the coronavirus pandemic. 

Still, a recent U.S. CBD Market Industry Update published by the Brightfield Group projects significant sales growth for CBD in 2022, with a holiday season jump and a possible boost from the passage of California Assembly Bill 45, which formally legalizes CBD production and sales in the state while also allowing it to be added to foods and marketed as a dietary supplement. This, coupled with the possibility that California may decide to restrict the sale of Delta-8 THC products to companies with state-issued marijuana licenses, may give non-intoxicating CBD products a much-needed lift in the market.

An increase of interest in hemp fiber and grain offers some reassurance to hemp farmers as well. In December, the National Hemp Association submitted a requested report to the White House predicting that hemp and fiber grain would generate a $32 billion dollar impact by 2030. As a crop that sequesters carbon dioxide and creates nutrient-rich soil (and therefore nutrient-rich produce), hemp shows great promise as a rotational crop among farmers who currently rotate corn, soy, and wheat. Meanwhile, hemp fiber has the potential to serve as the basis for thousands of products throughout the supply chain. 

The success of hemp fiber and grain will require a considerable investment of time, resources, education, and promotion and is not without challenges, but as big brands like Georgia-Pacific, Nike, and Patagonia announce initiatives to make hemp-based products, the wheels are already turning in hemp fiber’s favor. Farmers growing hemp fiber and grain can buy certified seed to minimize their risks (an option which does not exist for CBD plant seed), and the availability of contracts for growing hemp for both fiber and seed is increasing as manufacturers research more ways, both old and new, to make use of this versatile plant.


Debra BorchardtDecember 2, 2021


Despite the controversy over Delta-8, sales are beating some popular CBD companies. Hemp Benchmarks has been following the price of Delta-8 within the hemp industry and recently highlighted the company LFTD Partners (OTC: LSFP), whose sales rival many established CBD companies. 

CBD Fever Dreams

When the Farm Bill was passed in 2018, there were high hopes for the CBD industry and in particular for the hemp farmers. Hundreds of acres were grown, but the huge demand for CBD never materialized. There was demand, to be sure, but not at the levels the market had anticipated. This resulted in a glut of CBD biomass in the market and prices plunged. Farmers plowed over crops instead of harvesting due to the cost and many dramatically reduced the acres of hemp they were growing. 

Delta-8 Growth

Then Delta-8 came along and the farmers began to find a new market for their crops. It was discovered that within the language of the Farm Bill, only Delta-9 cannabis was carved out as an adult-use THC product, leaving Delta-8 in a grey area. Delta-8 is often referred to as cannabis light in that the psychoactive response is milder than Delta 9 cannabis. It is also extracted from hemp as opposed to the regular cannabis that produces the typical THC product. This loophole caught many off guard and with little regulation or oversight, the product began to take off. 

Several states have banned the product from being sold due to the lack of oversight. The cannabis industry seems mixed on whether it supports the product or not. Some are happy that it has helped out hemp farmers, while others see it as competition that isn’t subject to the same onerous regulations. In addition to that, the FDA noted that it has received several troubling reports on Delta-8. Seeing a Delta-8 company beat a highly regulated CBD company in revenue has got to hurt.

Lifted Made

LFTD Partners also known as Lifted Made, manufactures and sells branded products containing hemp-derived cannabinoids (e.g. delta-8-THC, delta-9-THC, delta-10-THC, THCV, THCO, CBDA, CBC, CBG, CBN, CBD), e-liquid, disposable nicotine vapes, kratom and kava products. In February 2020, LSFP acquired 100% of Warrender Enterprise Inc. d/b/a Lifted Made (formerly d/b/a Lifted Liquids). It recently announced that it was expanding its operations for the fourth time during the last 18 months, leasing an additional 8,000 square feet in a third building in Kenosha, WI. LSFP has also signed a letter of intent to acquire Savage Enterprises, owner of award-winning hemp-derived products brand Delta Extrax, sub-brand Chronix, Savage CBD, male enhancement products brand Vix, kratom and kava-based products brand Kanna, and plans to enter the California marijuana industry by purchasing Premier Greens LLC and MKRC Holdings, LLC. 

Two weeks ago, the company reported its third-quarter revenue had risen 32% to $8.8 million and net income grew by 40% to $2.2 million. Savage reported that it had revenues of $20 million in the third quarter, but doesn’t look to have Delta-8 products in its portfolio. Still, the pro-forma of the combined companies puts it near a $30 million quarter. 

CBD Companies Struggle

CBD brands have struggled under the massive amount of money it took to get established only to see competition muddy the landscape. CBD was being sold at grocery stores and gas stations. Consumers had no idea whether the cheap CBD at the gas station was the same, better, or worse than more reputable brands. With major restrictions on what CBD companies could say about themselves, consumers couldn’t even do their own research. Websites remain vague and companies that attempt to give consumers as much information as possible often get slapped by the FDA for making claims they can’t support with medical research. 

This year, a well-respected brand Plus Products essentially went bankrupt. Aligning itself with a major celebrity like John Legend didn’t help as the company became overwhelmed with debt. The stock has quit trading as the company restructures. In its last earnings report, Plus only delivered revenues of $4 million for the second quarter. 

While Charlotte’s Web (OTC: CWBHF) reported revenues of $23 million in the most recent third-quarter earnings report, this was down from 2020’s third-quarter revenue of $25 million. Another CBD with a large market share, CV Sciences (OTC: CVSI) reported that sales for the third quarter of 2021 were $5.1 million, which dropped 8% from $5.6 million in the third quarter of 2020. 

FDA Warns About Delta-8

In September, the Food & Drug Administration (FDA) issued a warning about Delta-8 THC noting that the product hasn’t been evaluated or approved by the agency. Granted the FDA’s opinion on anything cannabis-related is received with a healthy dose of skepticism. The FDA still hasn’t made any determination on CBD after years of discussion and research. In the warning notice, the FDA said that from December 2020 through July 2021, it had received adverse event reports from both consumers and law enforcement describing 22 patients who consumed delta-8 THC products and 14 went to a hospital or emergency room for treatment. 19 of these patients said they had eaten delta-8 THC food products. The adverse events included vomiting, hallucinations, trouble standing, and loss of consciousness. In addition to that, the FDA said that the national poison control centers received 661 exposure cases of delta-8 THC products between January 2018 and July 31, 2021, 660 of which occurred between January 1, 2021, and July 31, 2021. Of the 661 exposure cases:

  • 41% involved unintentional exposure to delta-8 THC and 77% of these unintentional exposures affected pediatric patients less than 18 years of age.
  • 39% involved pediatric patients less than 18 years of age
  • 18% required hospitalizations, including children who required intensive care unit (ICU) admission following exposure to these products.

In Closing

CBD companies were already facing a tsunami of challenges and the onslaught of the Delta-8 products has only added to those troubles. Until the cannabis industry decides to take a position on Delta-8, one way or the other, it is likely the CBD-only companies will have to find new ways to succeed. The patchwork approach by some states banning the product, while others allow it only creates more chaos for consumers. In the meantime, it looks as if the lack of regulations and customer demand will keep Delta-8 companies in business and possibly more successful than the CBD companies who are trying to play by the rules.

StaffNovember 22, 2021


High Tide Inc. (TSXV: HITI) (Nasdaq: HITI) announced it was buying 80% of NuLeaf Naturals, LLC for $31.24 million and will have a three-year option to acquire the remaining 20% of NuLeaf at any time. The total company is valued at $39 million. High Tide said that NuLeaf would be highly accretive noting that NuLeaf generated gross margins of 71% and Adjusted EBITDA1 margins of 25% during the 12 months ended September 30, 2021.

“With this announcement, we have doubled down on our efforts to become a global market leader with respect to hemp-derived CBD production and e-commerce sales. Our strategy is backed by numerous studies which predict that the global CBD market is set to grow exponentially over the coming years, with Fortune Business Insights projecting that it will reach US$56 billion by 2028, equating to a compound annual growth rate of 47%. High Tide is growing across all three categories within the cannabis ecosystem, including THC, CBD, and accessories. With the purchase of NuLeaf, we are now further vertically-integrated in our CBD business, just like we have been with regard to consumption accessories. As international markets open up and as export regulations evolve, NuLeaf’s cGMP-certified facility positions us to take advantage of the global CBD business opportunity,” said Raj Grover, President and Chief Executive Officer of High Tide. “Additionally, NuLeaf has developed customized manufacturing technology for vegan softgels, establishing them as one of very few manufacturers in the U.S. with this capability. Their portfolio also includes other innovative products including their Multicannabinoid oils and softgels. This transaction will provide us with meaningful cross-selling synergies and margin enhancement opportunities for FAB and Blessed CBD.”

Founded in 2014 with its headquarters in Denver, Colorado, NuLeaf is a market leader in the production and distribution of premium cannabidiol (CBD) wellness products. NuLeaf can produce 60,000 plant-based softgels per hour and is one of only a few manufacturers in the United States that can produce a vegan softgel. NuLeaf has a strong distribution reach in the natural products channel and recently secured an expansion with Sprouts Farmers Market from 33 retail locations to an additional 235 stores. Over the 12 months ended September 30, 2021, NuLeaf had over 5.1 million site visits and an average order value of US$120.

“We are excited to partner with Raj and the High Tide team to deliver the highest quality cannabinoid products in the world,” said Bo Shirley, Co-founder of NuLeaf Naturals. “Utilizing the latest in cannabinoid research, we continue to drive innovation and growth by launching unprecedented products that revolutionize the market. High Tide is a global leader in cannabis and together we look forward to expanding our market share and building the future of this industry.”

“This strategic alignment with High Tide will enable us to continue to deliver exceptional value to our customers and retail partners,” said Jaden Barnes, Co-founder of NuLeaf Naturals. “As part of the High Tide organization, we are well positioned to take the next steps in our growth strategy while maintaining our laser focus on delivering a world-class cannabis experience.”

Julie AitchesonNovember 4, 2021


There is a constant influx of new CBD, CBG, CBN, and synthetic products flooding the market and ever more consumers turning to them for relief from a range of conditions, relaxation, and a festive alternative to hangover-inducing substances. As regulators struggle to keep up with the seismic growth of the market, a new Leafreport survey sought to uncover how much CBD users are actually consuming and how they choose their dosages.

While some dosage schemes for CBD have been proposed, none have been implemented to date and there is still disagreement on the issue among medical professionals. This means that customers are left to labels, their own research and preferences, and the recommendations of others to determine what the optimal dose for their desired outcome might be. Leafreport’s survey captured US-based individuals ages 21 to 80 years of age. There were 1360 people who responded to the survey, 721 of whom are either using CBD or have experimented with it.

Leafreport’s findings showed that, of those surveyed, 71% of CBD users self-determine their own dosage without consulting a professional while 18% consulted with a doctor and 11% consulted with a CBD/cannabis industry professional. Even industry experts like CEO and Founder of The People’s Dispensary Christine De La Rosa (cited in the report) references the recommended dosage on the label and then adjusts it until she finds what works for her. She does add, however, that advice from a professional can be a helpful source of guidance, as is taking time to gauge your body’s response to a specific dosage. Author Anthony Schroeder (“7 Ways To Manage Pain With CBD”) shared the view that the dosage suggestion on a label should be considered a generic starting point to be increased or decreased based on factors like sensitivity, body weight, and pre-existing conditions.

So self-determining dosage using the label as a baseline may not be such a bad idea, but Leafreport’s survey shows that 26% of those surveyed don’t check for CBD concentration when shopping for a product and 22% don’t check the dose at all before consuming the product. 31% of consumers surveyed using CBD every day and 48% take the same dosage every time they consume CBD.  Again, a full 22% revealed that they don’t know how much they are taking because they never checked the dose. Leafreport’s survey concludes that not paying attention to potency or daily dosage can be problematic and even harmful, as CBD elicits “biphasic effects” at different doses. The survey summary cites the example of how a low dosage might alleviate anxiety while a higher dosage can elevate it. The advent of a standardized dosage scheme may not fully address this issue, as user responses and conditions are incredibly unique, pointing to the importance of obtaining professional advice on dosage, especially for less-experienced consumers. 

StaffAugust 31, 2021


Editors Note: This is a guest post.

During the past few years, there has been growing popularity regarding CBD. CBD stands for cannabidiol. It is one of the two main substances that is isolated from hemp. Many people enjoy using CBD to treat a wide variety of health issues, including depression, anxiety, and stress relief. Because depression is an issue that impacts people worldwide, new treatment options have been developed, including CBD. If you are struggling with depression, you should reach out to a mental health professional who can help you develop a comprehensive treatment plan that includes therapy, which might include CBD. How can CBD be used to treat depression if you visit a popular dispensary Glendale AZ location?

An Overview of CBD

CBD is one of the numerous substances isolated from hemp; however, the other primary substance is THC. THC stands for tetrahydrocannabinol and is responsible for the psychoactive effects of cannabis. Even though a lot of people believe CBD can get you high, this is not the case. CBD does not have any psychoactive effects. CBD has been found to be helpful to treat a wide variety of medical issues. Examples include stress relief, anxiety, depression, chronic pain, and sleep issues.

Furthermore, a prescription medication called epidiolex is used to treat certain types of seizure disorders. As more research is done on CBD, more benefits are being uncovered. This includes benefits related to CBD and the treatment of depression.

What Are the Signs and Symptoms of Depression?

Similar to other medical issues, depression can present in a variety of ways. There are a few common symptoms of depression, including:

  • Many people who develop depression have issues falling asleep or staying asleep at night.
  • Individuals with depression often experience changes in their eating habits, either eating significantly more or less.
  • People with depression also feel guilty about things that are not their fault.
  • Depression can also present with changes in an emotional state, leading to major mood swings. People with depression may have rapid mood swings ranging from happiness to sadness and anger.
  • There are certain situations where people with depression may develop suicidal ideation.

Anyone who suffers from depression deserves to have access to a trained mental health professional who can help them address these concerns. If you are working with a mental health professional to develop a treatment plan for depression, CBD could be right for you.

Can CBD Be Used To Treat Depression?

Yes, CBD can be used to treat depression. Many prescription medications treat depression by altering levels of serotonin, which is a neurotransmitter in the brain that causes people to feel happy. There is some evidence that CBD can alter serotonin levels, making it an effective treatment for depression. Even though CBD can be helpful in certain cases, it also has the potential to interfere with other prescription medications. Therefore, if you are taking prescription medications for depression, you need to talk to your doctor ahead of time. That way, you can figure out if CBD will interact with anything else you are taking. This could have an impact on your treatment plan.

How Do You Choose the Right CBD Product?

If you are trying to find CBD that can help you treat depression, you need to choose the right product. In particular, you need to pay attention to whether the product has any THC in it. If you take something with THC, you are going to feel psychoactive effects. Therefore, you need to make sure you do not operate heavy machinery. You should also think about how you want to consume CBD. Some people prefer to inhale it directly, while others prefer to use substances they can apply to the skin’s surface. Make sure you talk to a professional about the type of CBD product that is right for you. That way, you are comfortable using the CBD treatment method you purchase.

Talk To a Professional About CBD for the Treatment of Depression

If you or someone you know is suffering from symptoms of depression, remember that you are not alone. There are professionals who can help you. CBD can help you treat depression in the right situations. Before you try CBD for the first time, be sure to talk to a doctor. Then, if you have questions about finding the right CBD product, reach out to someone who has experience in this area. That way, you know you will find CBD products that can help you effectively treat depression. It could be a part of your comprehensive treatment plan.



Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.


We respect your privacy. See our privacy policy.

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

@GreenMarketRpt – 3 days

We are stoked to open up nominations for the 1st ever GMR Cannabis Tech Awards. They will be announced at the GMR T…

@GreenMarketRpt – 4 days

Flower One’s Revenue Drops In Fourth Quarter, Restructures Debt Payments

@GreenMarketRpt – 4 days

SPACS Losing Their Mojo As Deals Get Pushed Out

Back to Top

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.


We respect your privacy. See our privacy policy.